ZFSW
Cancer vaccine developer
ZFSW, founded in July, 1995 and headquartered in Chongqing, is an anti-cancer vaccine developer. The founder is Jiang Rensheng. Listed on the SZSE on September 28, 2010, the company's major shareholders are Jiang Rensheng, Jiang Lingfeng and Wu Guanjiang. Rivals that have direct and indirect competition with ZFSW include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
The official results of the French parliamentary elections were announced, and the ruling party coalition held a relatively large number of seats
Shenzhen textile A: the order of line 7 is full, and the production line speed is climbing
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Real Estate, Consumer Discretionary, IndustrialsTech for Global, Globalization Footprints of the Established and the New
Research
Real Estate, Consumer Discretionary, IndustrialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
Half day main capital net inflow of power equipment, non bank finance, selling banks, etc
RNA Biotech Therorna Bags Over CNY 280 Mn in Series A Financing Round
Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.
Jun 23, 2022 03:45 PM
AI-driven pharmaceutics Company Helixon Raise CNY 500 Mn in Series A Round
As one of the key players in computational biology, Helixon received recognition from the capital market for its innovation in machine learning algorithms and data acquisition technologies which reconstruct the drug development process and improve the efficiency of new drug development.
Jun 22, 2022 06:13 PM
AI-driven Biotech Galixir Nominates Preclinical Candidate in Treating Autoimmune Disease
Founded in 2019, Galixir named a Preclinical Candidate (PCC) for the treatment of Autoimmune Disease (AID) which was screened out of around 80 compounds via its proprietary platform, Pyxir®, making it another top-ranking China-based AI-driven drug discovery company.
Jun 21, 2022 01:44 PM
Monitoring of main funds of star mine: Top 10 list of early trading
Pharmaceutical and biological stocks fell sharply in early trading
US Senate committee to investigate the role of cryptocurrency in cyber crime
A breakthrough in cell therapy of solid tumor by Zhifei biological joint stock company